此范文为中译英

原文：

血凝酶是1936 年从南美巴西矛头蝮蛇BothropsAtrox 一种毒蛇的毒液中分离出来的一种单链糖蛋白。血凝酶被国际著名的《马丁代尔大药典》第31版等多版收载。作为中国目前最主要的止血药之一，最近三年里血凝酶在国内处方药市场上占据了33％的市场份额，注射用血凝酶目前中国的平均零售价约￥57（中标价格约￥47）。销售金额和销售数量走势呈现出平稳上升的趋势，表明该产品正处于市场的成熟期。目前国内血凝酶制剂为注射用血凝酶，但因为保护期未到，无法仿制。
我们可以采取进口血凝酶注射液，作为进军止血药市场切入点，填补国内血凝酶注射液制剂的一项空白，必将取得良好的经济效益和社会效益。

译文：

Hemocoagulase was a single-chain glycoprotein separated from poison venom of certain kind of Brazilian BothropsAtrox in South America in 1936. Hemocoagulase has been registered in world famous MARTINDALE the Extra Pharmacopoeia thirty-first edition and other editions. Known as one of the most mainly haemostats, hemocoagulase has possessed 33% of market shares of domestic prescribed drug over recent 3 years, and the average retail price of hemocoagulase injection in China is about ￥57 (the bid-winning price is about ￥47) at present. Its market sale and market amounts have remained stably ascendant tendency, indicating that the product is in the maturation period of market. Nowadays, domestic hemocoagulase preparation is hemocoagulase injection, which cannot be imitated for its protection period.
We can adopt import hemocoagulase injection as the key point to develop the haemostat market, compensating for the blank of domestic hemocoagulase injection, which will undoubtedly make good economic returns and social effects.